SAN DIEGO--(BUSINESS WIRE)--Nov. 30, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced Edmund P. Harrigan, M.D., has joined its
Board of Directors. Dr. Harrigan is a board-certified neurologist with
25 years of executive leadership experience in the pharmaceutical
industry, most recently serving as Senior Vice President, Worldwide
Safety and Regulatory at Pfizer Inc.
“Ed’s extensive experience with CNS drug development, coupled with his
leadership roles in worldwide regulatory and business development
operations will be invaluable to ACADIA as we deliver on our vision of
building a leading CNS company dedicated to improving the lives of
patients through innovative new medicines,” said Leslie L. Iversen,
Ph.D., Chairman of ACADIA’s Board of Directors.
Dr. Harrigan’s executive roles at Pfizer span over 18 years and across
multiple functions. He served as Senior Vice President of Worldwide
Safety and Regulatory for Pfizer from 2012 to 2015, where he led a
3,500-person team in 80 countries that was responsible for collecting,
interpreting and reporting clinical safety data for more than 600
marketed products, and managed regulatory interactions with global
health agencies. Dr. Harrigan’s previous executive leadership roles at
Pfizer include serving as Senior Vice President, Head of Worldwide
Business Development, Senior Vice President, Head of Worldwide
Regulatory Affairs and Quality Assurance, and Vice President, Head of
Neuroscience and Ophthalmology. Earlier in his career at Pfizer, Dr.
Harrigan served as Vice President of Clinical Development, Therapeutic
Area Head, CNS and Pain.
Before entering the pharmaceutical industry in 1990, Dr. Harrigan was a
practicing neurologist for seven years. He currently serves on the Board
of Directors of Karuna Pharmaceuticals Inc. Dr. Harrigan earned his B.A.
degree in Chemistry from St. Anselm College and holds an M.D. from the
University of Massachusetts at Worcester. He also attended the Brain
Research Institute at the University of California, Los Angeles.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA has a pipeline of product
candidates led by NUPLAZID™ (pimavanserin), for which we have submitted
a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA
and which has the potential to be the first drug approved in the United
States for this condition. The FDA has classified the NUPLAZID NDA as
having Priority Review status. Pimavanserin is also in Phase II
development for Alzheimer’s disease psychosis and has successfully
completed a Phase II trial in schizophrenia. ACADIA also has
clinical-stage programs for glaucoma and, in collaboration with
Allergan, Inc., for chronic pain. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the potential for NUPLAZID
(pimavanserin) to be the first drug approved in the United States for
Parkinson’s disease psychosis (PDP) and the potential timing of such
approval, if approved at all, by the FDA; the benefits to ACADIA of Dr.
Harrigan joining its Board of Directors; the progress, timing and
results of ACADIA’s drug discovery and development programs, either
alone or with a partner, including the progress and expected timing of
clinical trials; and the benefits to be derived from ACADIA’s product
candidates, including pimavanserin. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in drug
discovery, development, approval and commercialization, and
collaborations with others, and the fact that past results of clinical
trials and past regulatory decisions may not be indicative of future
trial results or future regulatory decisions, respectively. For a
discussion of these and other factors, please refer to ACADIA’s annual
report on Form 10-K for the year ended December 31, 2014 as well as
ACADIA’s subsequent filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151130005320/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director of